Bio-Techne Corporation

TECHNASDAQHealthcare● Active

$53.12

+$1.13(+2.17%)

Market Cap$8.3B

P/E Ratio—

52W High$72.16

52W Low$43.2

Avg Volume2.6M

Open$52.43

Beta1.36

Free Cash Flow Financials Revenue

Bio-Techne Corporation (TECH) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

TECH · free cash flow · updated Jun 8, 2026

Core FCF metrics

TECH · FCF · TTM · margin & CAGR

Free cash flow was $256.6M for FY2025 (fiscal year ending 2025-06-30), up 8.7% year-over-year The FCF margin was 21.0%. Five-year CAGR stands at +10.8%.

FY2025 Free Cash Flow$256.6M▲ +8.7% YoY

Trailing 12M (TTM)$269.6Mtrailing 4 quarters sum

FCF Margin21.0%$256.6M ÷ revenue

3-Year CAGR-2.9%FY2022 → FY2025

5-Year CAGR+10.8%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

TECH · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$287.6M(31M)$256.6M▲ +8.7%21.0%

FY2024$299.0M(63M)$236.1M▲ +9.2%20.4%

FY2023$254.4M(38M)$216.1M▼ 22.9%19.0%

FY2022$325.3M(45M)$280.4M▼ 8.9%25.4%

FY2021$352.2M(44M)$307.9M▲ +100.6%33.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

TECH · P/FCF · FCF yield · FCF per share

Bio-Techne Corporation (TECH) trades at a FCF yield of 3.24% and a price-to-free-cash-flow ratio of 31.1x. FCF per share stands at $1.71, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

3.24%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$1.71

TTM FCF ÷ Shares Outstanding

Price / FCF

x31.1

Share Price ÷ FCF per Share

EV / FCF (TTM)

x31.1

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-06-30

Cash flow statement summary

TECH · cash flow statement · operating / investing / financing

For FY2025, Bio-Techne Corporation generated $287.6M in operating cash flow and spent 31M in capital expenditures, yielding $256.6M in free cash flow.

Operating Activities

+$287.6M

Cash from core business operations

2025-06-30

Investing Activities

−$35.2M

CapEx, acquisitions & investments

2025-06-30

Financing Activities

−$253.9M

Buybacks, dividends & debt

2025-06-30

FCF FormulaOperating CF ($287.6M) − |CapEx| (31M) = FCF ($256.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

TECH vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Bio-Techne CorporationYOU

TECH

$256.6M+8.7%21.0%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Bio-Techne Corporation (TECH) reported free cash flow of $256.6M for FY2025 (fiscal year ending 2025-06-30), up 8.7% year-over-year. The FCF margin was 21.0%.

Based on available data, Bio-Techne Corporation has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $307.9M in FY2021. The 5-year CAGR stands at +10.8%.

Bio-Techne Corporation's FCF yield is 3.24% and price-to-FCF ratio is 31.1x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

TECH free cash flow · 8 questions

Bio-Techne Corporation free cash flow was $256.6M for FY2025, up 8.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $269.6M.

TECH free cash flowTECH FCFTECH FCF 2025TECH free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Bio-Techne Corporation · Bio-Techne Corporation SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026